HSE wants Pembro for all women with cervical cancer

HSE wants Pembro for all women with cervical cancer

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

The HSE wants the state to fund the drug Pembro for more women with cervical cancer.

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Under this proposal, all patients with cervical cancer would be able to access the drug. It typically takes about eight months to see whether individual patients respond to Pembrolizumab, which is called Pembro for short.

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post